These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25487848)

  • 1. [Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples].
    Faillie JL; Suissa S
    Therapie; 2015; 70(3):259-63. PubMed ID: 25487848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immortal time bias in pharmaco-epidemiology.
    Suissa S
    Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
    Targownik LE; Suissa S
    Am J Gastroenterol; 2015 Dec; 110(12):1647-50. PubMed ID: 26323186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoepidemiology in pregnancy.
    Benevent J; Araujo M; Hurault-Delarue C; Montastruc JL; Sommet A; Lacroix I; Damase-Michel C
    Therapie; 2019 Apr; 74(2):289-300. PubMed ID: 30797568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.
    Daniel S; Koren G; Lunenfeld E; Levy A
    Am J Obstet Gynecol; 2015 Mar; 212(3):307.e1-6. PubMed ID: 25265406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The limitations of observation studies for decision making regarding drugs efficacy and safety.
    Gueyffier F; Cucherat M
    Therapie; 2019 Apr; 74(2):181-185. PubMed ID: 30514576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.
    Acton EK; Willis AW; Hennessy S
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):9-18. PubMed ID: 36216785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of self-controlled designs in pharmacoepidemiology.
    Hallas J; Pottegård A
    J Intern Med; 2014 Jun; 275(6):581-9. PubMed ID: 24635348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Future Perspective of Pharmacoepidemiology in the "Big Data Era" and the Growth of Information Sources].
    Macías Saint-Gerons D; de la Fuente Honrubia C; de Andrés Trelles F; Catalá-López F
    Rev Esp Salud Publica; 2016 Dec; 90():e1-e7. PubMed ID: 27905352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias.
    Gardarsdottir H; Egberts TC; Stolker JJ; Heerdink ER
    Am J Epidemiol; 2009 Aug; 170(3):280-5. PubMed ID: 19498074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?
    Palmaro A; Boucherie Q; Dupouy J; Micallef J; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):544-553. PubMed ID: 28266748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bias and confounding: pharmacoepidemiological study using administrative database].
    Nojiri S
    Yakugaku Zasshi; 2015; 135(6):793-808. PubMed ID: 26028416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.
    Kiri VA; Pride NB; Soriano JB; Vestbo J
    Am J Respir Crit Care Med; 2005 Aug; 172(4):460-4. PubMed ID: 15901610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: "Immortal time bias in pharmacoepidemiology".
    Kiri VA; Mackenzie G
    Am J Epidemiol; 2009 Sep; 170(5):667-8; author reply 668-9. PubMed ID: 19648577
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of immortal person-time when outcomes are nonfatal.
    Liang C; Seeger JD; Dore DD
    Ann Epidemiol; 2016 Mar; 26(3):212-7. PubMed ID: 26847051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.
    Liu J; Weinhandl ED; Gilbertson DT; Collins AJ; St Peter WL
    Kidney Int; 2012 Feb; 81(4):341-50. PubMed ID: 22089946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immortal time bias in observational studies of drug effects.
    Suissa S
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):241-9. PubMed ID: 17252614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies.
    Palmaro A; Moulis G; Despas F; Dupouy J; Lapeyre-Mestre M
    Fundam Clin Pharmacol; 2016 Dec; 30(6):616-624. PubMed ID: 27351637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study designs in paediatric pharmacoepidemiology.
    Verhamme K; Sturkenboom M
    Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():67-74. PubMed ID: 21107830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.